Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Researchers Create Highly Accurate Non-Invasive Test for Major Liver Diseases

By LabMedica International staff writers
Posted on 15 Jul 2022

Non-alcoholic steato-hepatitis (NASH) is the most severe form of non-alcoholic fatty liver disease (NAFLD) and is diagnosed in approximately 60% of NAFLD patients. More...

NASH puts people at risk of progressing to advanced liver diseases such as liver fibrosis, cirrhosis, and liver cancer. NAFLD affects approximately 52 million people in Europe and 64 million people in the US, costing USD 138 billion annually to the European and US healthcare systems combined. Currently, NASH can only be diagnosed with invasive liver biopsy, which is the standard of diagnosis, but this is expensive and has co-morbidities and complications. There are also no reliable blood (i.e. liquid biopsy) tests for the diseases because of low sensitivity and specificity. Current blood tests are also unable to reliably predict NASH and fibrosis staging. Now, researchers in metabolic sciences have developed a liquid biopsy test that uses two circulating proteins and is highly accurate, sensitive, and specific for both NASH and liver fibrosis. For the first time, a non-invasive test will allow for the determination of staging of both diseases without recurring to invasive liver biopsy.

Researchers at King’s College London (London, UK) have identified two protein biomarkers, PLIN2 and RAB14, that were used as part of an algorithm to identify people with NASH and/or liver fibrosis. The researchers tested the ability of these proteins to detect NASH in cohorts of people with either biopsy-confirmed NASH or liver fibrosis. The algorithms, which used A.I., gave impressive results including a sensitivity of 88-95%, a specificity of 90%-100%, and an overall accuracy of 92-93% for NASH. For fibrosis, results were even better, with a sensitivity of 99-100%, specificity of 90-96%, and accuracy of 98-99%. As well as being much more accurate than all other currently available biomarkers, it is now possible to predict the stages of the diseases without invasive liver biopsy.

These results show that the PLIN2/RAB14-based liquid biopsy can provide rapid and cost-effective testing to combat the growing epidemic of NASH and liver fibrosis. This will be an invaluable tool in diagnosing and monitoring cases of liver diseases, enabling people to receive earlier treatment. The researchers also believe that the testing will allow for the improved capacity for researchers to study NASH and liver fibrosis in the general population, including disease progression, and record the effects of treatment, from lifestyle to surgical and pharmacological interventions. No NASH drug has been approved by the FDA or EMA due to the lack of an accurate, reliable, and non-invasive test. Between 65-73% of patients that currently enroll in clinical trials for NASH-related therapies are found to be ineligible for the trial due to screen failure. The new test is expected to significantly reduce screen failures in clinical trials and improve the chances of new life-saving drugs reaching the market.

“This blood test will allow to define the real prevalence of NASH in large and small populations, including children and adolescents, avoiding the need for invasive liver biopsy,” said Geltrude Mingrone, Professor of Diabetes and Nutrition at the School of Cardiovascular and Metabolic Medicine & Sciences. “Importantly, it will also allow to monitor the efficacy of NASH treatments over time, reducing screen failures and helping generate better drugs.”

Related Links:
King’s College London 


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.